APA (7th ed.) Citation

Shadman, M., Flinn, I. W., Levy, M. Y., Porter, R. F., Burke, J. M., Zafar, S. F., . . . Sharman, J. P. (2023). Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: A phase 2, open-label, single-arm study. The Lancet. Haematology, 10(1), e35. https://doi.org/10.1016/S2352-3026(22)00320-9

Chicago Style (17th ed.) Citation

Shadman, Mazyar, et al. "Zanubrutinib in Patients with Previously Treated B-cell Malignancies Intolerant of Previous Bruton Tyrosine Kinase Inhibitors in the USA: A Phase 2, Open-label, Single-arm Study." The Lancet. Haematology 10, no. 1 (2023): e35. https://doi.org/10.1016/S2352-3026(22)00320-9.

MLA (9th ed.) Citation

Shadman, Mazyar, et al. "Zanubrutinib in Patients with Previously Treated B-cell Malignancies Intolerant of Previous Bruton Tyrosine Kinase Inhibitors in the USA: A Phase 2, Open-label, Single-arm Study." The Lancet. Haematology, vol. 10, no. 1, 2023, p. e35, https://doi.org/10.1016/S2352-3026(22)00320-9.